10348-83-1

Basic information

• Product Name: 3t-phenoxy-acrylaldehyde
• Synonyms: 3t-phenoxy-acrylaldehyde
• CAS NO: 10348-83-1
• Molecular Weight: 148.161
• Mol File: 10348-83-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3t-phenoxy-acrylaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3t-phenoxy-acrylaldehyde(10348-83-1)
• EPA Substance Registry System: 3t-phenoxy-acrylaldehyde(10348-83-1)

Safety Data

• Hazardous Substances Data: 10348-83-1(Hazardous Substances Data)

Upstream product

• 624-67-9 Propargylic aldehyde 
• 108-95-2 phenol 
• 50-00-0 formaldehyd 
• 2120-70-9 2-phenoxyethanal 

Downstream Products

• 1450-85-7 2-thioxopyrimidine 

Relevant articles and documents

HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETOEPOXIDE COMPOUNDS

Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, an alpha-ketoepoxide group, such as an alpha-ketothio group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, autosomal dominant disorders, e.g., spinal muscular atrophy and Huntington's disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or to stimulate hematopoietic cells ex vivo.

HISTONE DEACETYLASE INHIBITORS BASED ON ALPHACHALCOGENMETHYLCARBONYL COMPOUNDS

Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, an alpha-chalcogenmethylcarbonyl group, such as an alpha-ketothio group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, autosomal dominant disorders, e.g. spinal muscular atrophy and Huntington’s disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or for stimulating hematopoietic cells ex vivo.